Public health measures in the control of viral hepatitis: A World Health Organization perspective for the next millennium

Journal of Gastroenterology and Hepatology (Australia)

Volumn 17, Issue SUPPL. 4, 2002, Pages

  Lavanchy, Daniel ^a  

^a WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; ANTIVIRUS AGENT; HEPATITIS VACCINE; RIBAVIRIN;

DEVELOPING COUNTRY; DISEASE CONTROL; DRUG ABUSE; DRUG TARGETING; HEALTH; HEALTH CARE; HEALTH CARE ORGANIZATION; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS E; HIGH RISK POPULATION; HUMAN; IMMUNIZATION; IMMUNOTHERAPY; INFECTION; LIFE EXPECTANCY; LIVER CANCER; MORBIDITY; MORTALITY; POPULATION GROWTH; POVERTY; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROPHYLAXIS; PUBLIC HEALTH; REVIEW; SANITATION; SEXUAL TRANSMISSION; VACCINATION; VERTICAL TRANSMISSION; VIRUS CARRIER; VIRUS HEPATITIS; VIRUS IMMUNITY; VIRUS TRANSMISSION;

EID: 0036954140     PISSN: 08159319     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1440-1746.17.s4.9.x     Document Type: Review

References (104)

1. The World Health Organization. World Health Report. Geneva: WHO; 1999.
2. Melnick JL. History and epidemiology of hepatitis A virus. J. Infect. Dis. 1995; 171 (Suppl. 1): S2-8.
3. Papaevangelou G. Epidemiology of hepatitis A in Mediterranean countries. Vaccine 1992; 10 (Suppl. 1): S63-6.
4. Shapiro CN, Coleman PJ, McQuillan GM, Alter MJ, Margolis HS. Epidemiology of hepatitis A: seroepidemiology and risk groups in the USA. Vaccine 1992; 10 (Suppl. 1): S59-62.
5. Berthelot P. Hépatite virale A: Une épidémiologie mouvante qui va faire changer nos concepts. Gastroenterologie Clinique Et Biologique. 1992; 16: 669-70.
6. Feinstone SM. Hepatitis A: epidemiology and prevention. Euro. J. Gastroenterol. Hepatol. 1996; 8: 300-5.
7. Gay NJ. A model of long-term decline in the transmissibility of an infectious disease: implications for the incidence of hepatitis A. Int. J. Epidemiol. 1996; 25: 854-61.
8. Dienstag JL. Hepatitis A virus: virologic, clinical, and epidemiologic studies. Hum. Pathol. 1981; 12: 1097-106.
9. Zuckerman AJ. Human viral hepatitis. Pharmacol. Ther. 1980; 10: 1-13.
10. Rubin E. Acute and chronic viral hepatitis. Fed. Proc. 1979; 38: 2665-73.
11. Purcell RH. The viral hepatitides. Hosp. Pract. 1978; 13: 51-63.
12. Hepatitis A vaccines. World Health Organization position paper. Weekly Epidemiol. Rec. 2000; 75: 38-43.
13. Arankalle VA, Chobe LP, Jha J, Chadha MS et al. Aetiology of acute sporadic non-A, non-B viral hepatitis in India. J. Med. Virol. 1993; 40: 121-5.
14. Balayan MS. Epidemiology of hepatitis E virus infection. J. Viral Hepat. 1997; 4: 155-65.
15. Purcell RH, Tsarev SA. Seroepidemiology of hepatitis E. In: Buisson Y, Coursaget P, Kane M, eds. Enterically-Transmitted Hepatitis Viruses. Joue-les-Tours: La Simarre. 1996; 153-66.
16. Skidmore SJ, Yarbough PO, Gabor KA, Reyes GR. Hepatitis E virus: the cause of a waterbourne hepatitis outbreak. J. Med. Virol. 1992. 87: 58-60.
17. Acharya SK, Dasarathy S, Kumer TL et al. Fulminant hepatitis in a tropical population: Clinical course, cause, and early predictors of outcome. Hepatology 1996; 23: 1448-55.
18. Hussaini SH, Skidmore SJ, Richardson P, Sherratt LM, Cooper BT, O'Grady JG. Severe hepatitis E infection during pregnancy. J Viral Hepat. 1997; 4: 51-4.
19. van Cuyck-Gandré H, Cockman-Thomas R, Caudill JD. Experimental African HEV infection in cynomolgus macaques (Macaca fascicularis). J. Med. Virol. 1998; 55: 197-202.
20. Arankalle VA, Chadha MS, Dama BM, Tsarev SA, Purcell RH, Banerjee K. Role of immune serum globulins in pregnant women during an epidemic of hepatitis E. J. Viral Hepat. 1998; 5: 199-204.
21. Kane M, Clements J, Hu D. Disease control priorities in developing countries. In: Jamison DT, Mosley WH, Measham AR, Bobadilla J, eds. Disease control priorities in developing countries. New York: Oxford University Press, 1993; 330.
22. World Health Organization. Hepatitis C. Weekly Epidemiol. Rec. 1997; 72: 65-9.
23. Simonsen L, Kane A, Lloyd J, Zaffran M, Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull.World Health Organ. 1999; 77: 789-800.
24. World Health Organization, Global Programme for Vaccines and Immunization. Hepatitis B control through immunization; 1996. Report No.: WHO, GPV/SAGE.96/ WP.02; Geneva: WHO.
25. Viviani S, Jack A, Bah E, Montesano R. I1 carcinoma epatocellulare: un cancro prevenibile. Epidemiologia E Prevenzione1997; 21: 129-36.
26. Liao SS, Li RC, Li Het al. Long-term efficacy of plasma-derived hepatitis B vaccine: a 15-year follow-up study among Chinese children. Vaccine 1999; 17: 2661-6.
27. Lee MS, Kim DH, Kim Het al. Hepatitis B vaccination and reduced risk of primary liver cancer among male adults: a cohort study in Korea. Int. J. Epidemiol. 1998; 27: 316-19.
28. Kammerlander R, Zimmermann H. Übertragungswege der Hepatitis B. Sozial- Und Präventivmedizin 1998; 43 (Suppl. 1): S31-3, S105-7.
29. van Duynhoven YT, van de Laar MJ, Schop WA et al. Prevalence and risk factors for hepatitis B virus infections among visitors to an STD clinic. Genitourinary med. 1997; 73: 488-92.
30. Edmunds WJ, Medley GF, Nokes DJ. The transmission dynamics and control of hepatitis B virus in The Gambia. Stat. med. 1996; 15: 2215-33.
31. Corona R, Caprilli F, Giglio A et al. Risk factors for hepatitis B virus infection among heterosexuals attending a sexually transmitted diseases clinic in Italy: role of genital ulcerative diseases. J. Med. Virol. 1996; 48: 262-6.
32. Hou MC, Wu JC, Kuo BI et al. Heterosexual transmission as the most common route of acute hepatitis B virus infection among adults in Taiwan-the importance of extending vaccination to susceptible adults. J. Infect. Dis. 1993; 167: 938-41.
33. Petersen EE, Clemens R, Bock HL, Friese K, Hess G. Hepatitis B and C in heterosexual patients with various sexually transmitted diseases. Infection 1992; 20: 128-31.
34. Barrett CL, Austin H, Louv WC, Alexander WJ, Hadler SC. Risk factors for hepatitis B virus infection among women attending a clinic for sexually transmitted diseases. Sex. Transm. Dis. 1992; 19: 14-18.
35. Gan CY, Yap SF, Ngeow YF, Wong HC. Hepatitis B infection among Chinese STD patients in Kuala Lumpur, Malaysia. Sex. Transm. Dis. 1991; 18: 84-8.
36. Struve J, Giesecke J, Lindh G, Weiland O. Heterosexual contact as a major route for transmission of acute hepatitis B among adults. J. Infect. 1990; 20: 111-21.
37. van Doornum GJ, Hooykaas C, Cuypers MT, van der Linden MM, Coutinho RA. Prevalence of hepatitis C virus infections among heterosexuals with multiple partners. J. Med. Virol. 1991; 35: 22-7.
38. Lee SD, Chan CY, Wang YJ et al. Seroepidemiology of hepatitis C virus infection in Taiwan. Hepatology 1991; 13: 830-3.
39. Kolho E, Naukkarinen R, Ebeling F, Rasi V, Ikkala E, Krusius T. Transmission of hepatitis C virus to sexual partners of seropositive patients with bleeding disorders: a rare event. Scand. J. Infect. Dis. 1991; 23: 667-70.
40. Shev S, Wejstål R, Wahl M, Hermodsson S, Norkrans G. The lack of transmission of NANB/C hepatitis between acute and chronically infected patients and their heterosexual partners. Scand. J. Infect. Dis. 1991; 23: 407-11.
41. Melbye M, Biggar RJ, Wantzin P, Krogsgaard K, Ebbesen P, Becker NG. Sexual transmission of hepatitis C virus: cohort study (1981-9) among European homosexual men. B. M. J. 1990; 301: 210-12.
42. Schulman S, Grillner L. Antibodies against hepatitis C in a population of Swedish haemophiliacs and heterosexual partners. Scand. J. Infect. Dis. 1990; 22: 393-7.
43. Fabris P, Infantolino D, Biasin MR et al. High prevalence of HCV-RNA in the saliva cell fraction of patients with chronic hepatitis C but no evidence of HCV transmission among sexual partners. Infection 1999; 27: 86-91.
44. Brusaferro S, Barbone F, Andrian Pet al. A study on the role of the family and other risk factors in HCV transmission. European Journal Of Epidemiology 1999; 15: 125-32.
45. Rooney G, Gilson RJ. Sexual transmission of hepatitis C virus infection. Sex. Transm. Infect. 1998; 74: 399-404.
46. Ross RS, Viazov S, Varenholz C, Roggendorf M. Inquiries on intraspousal transmission of hepatitis C virus: benefits and limitations of genome sequencing and phylogenetic analysis. Forensic Sci. Int. 1999; 100: 69-76.
47. Sladden TJ, Hickey AR, Dunn TM, Beard JR. Hepatitis C transmission on the north coast of New South Wales: explaining the unexplained. Med. J. Aust. 1997; 166: 290-3.
48. Sachithanandan S, Fielding JF. Low rate of HCV transmission from women infected with contaminated anti-D immunoglobulin to their family contacts. Ital. J. Gastroentero. Hepatol. 1997; 29: 47-50.
49. Diago M, Zapater R, Tuset C et al. Intrafamily transmission of hepatitis C virus: sexual and non-sexual contacts. J. Hepatol. 1996; 25: 125-8.
50. Demelia L, Vallebona E, Poma R, Sanna G, Masia G, Coppola RC. HCV transmission in family members of subjects with HCV related chronic liver disease. Euro. J. Epidemiol. 1996; 12: 45-50.
51. Scotto G, Savastano AM, Fazio V. Sexual transmission of hepatitis C virus infection. Euro. J. Epidemiol. 1996; 12: 241-4.
52. Thomas DL, Zenilman JM, Alter HJ et al. Sexual transmission of hepatitis C virus among patients attending sexually transmitted diseases clinics in Baltimore - an analysis of 309 sex partnerships. J. Infect. Dis. 1995; 171: 768-75.
53. Zhao XP, Yang DL, Tang ZY et al. Infectivity and risk factors of hepatitis C virus transmission through sexual contact. J. Tongji Med. Uni. 1995; 15: 147-50.
54. David XR, Blanc P, Pageaux GP et al. Transmission familiale du virus de l'hépatite C. Gastroenterologie Clinique Et Biologique. 1995; 19: 150-5.
55. Daikos GL, Lai S, Fischl MA. Hepatitis C virus infection in a sexually active inner city population. The potential for heterosexual transmission. Infection 1994: 22: 72-6.
56. Gabrielli C, Zannini A, Corradini R, Gafa S. Spread of hepatitis C virus among sexual partners of HCVAb positive intravenous drug users. J. Infect. 1994; 29: 17-22.
57. Shev S, Hermodsson S, Lindholm A, Malm E, Widell A, Norkrans G. Risk factor exposure among hepatitis C virus RNA positive Swedish blood donors - the role of parenteral and sexual transmission. Scand. J. Infect. Dis. 1995; 27: 99-104.
58. García-Bengoechea M, Cortés A, López P et al. Intra-familial spread of hepatitis C virus infection. Scand. J. Infect. Dis. 1994; 26: 15-18.
59. Lissen E, Alter HJ, Abad MA et al. Hepatitis C virus infection among sexually promiscuous groups and the heterosexual partners of hepatitis C virus infected index cases. Euro. J. Clin. Micro. Infect. Dis. 1993; 12: 827-31.
60. Hallam NF, Fletcher ML, Read SJ, Majid AM, Kurtz JB, Rizza CR. Low risk of sexual transmission of hepatitis C virus. J. Med. Virology 1993; 40: 251-3.
61. Gordon SC, Patel AH, Kulesza GW, Barnes RE, Silverman AL. Lack of evidence for the heterosexual transmission of hepatitis C. Am. J. Gastroenterol. 1992; 87: 1849-51.
62. Brackmann SA, Gerritzen A, Oldenburg J, Brackmann HH, Schneweis KE. Search for intrafamilial transmission of hepatitis C virus in hemophilia patients. Blood1993; 81; 1077-82.
63. Salvaggio A, Conti M, Albano A et al. Sexual transmission of hepatitis C virus and HIV-1 infection in female intravenous drug users. Euro. J. Epidemiol. 1993; 9: 279-84.
64. Ricchi E, Borderi M, Costigliola P, Miniero R, Sprovieri G, Chiodo F. Anti-hepatitis C virus antibodies amongst Italian homo-bisexual males. Euro. J. Epidemiol. 1992; 8: 804-7.
65. Corona R, Prignano G, Mele A et al. Heterosexual and homosexual transmission of hepatitis C virus: relation with hepatitis B virus and human immunodeficiency virus type 1. Epidemiol. Infect. 1991; 107: 667-72.
66. Kaldor JM, Archer GT, Buring ML et al. Risk factors for hepatitis C virus infection in blood donors: a case-control study. Med. J. Aust. 1992; 157: 227-30.
67. Mast EE, Alter MJ, Margolis HS. Strategies to prevent and control hepatitis B and C virus infections: a global perspective. Vaccine1999; 17: 1730-3.
68. World Health Organization. Global Surveillance and Control of Hepatitis C. J. Med. Virology 1999; 6: 35-47.
69. Schalm SW. Chronic hepatitis B: diagnosis and treatment. Postgrad. Med. J. 1986; 62(Suppl. 2): 11-20.
70. Thomas HC, Scully LJ. Antiviral therapy in hepatitis B infection. Br. Med. Bull. 1985; 41: 374-80.
71. Perrillo RP. Antiviral therapy of chronic hepatitis B: past, present, and future. J. Hepatol. 1993; 17 (Suppl. 3): S56-63.
72. Lok AS, Wu PC, Lai CL et al. A controlled trial of interferon with or without prednisone priming for chronic hepatitis B. Gastroenterology 1992; 102: 2091-7.
73. Perrillo RP. Antiviral agents in the treatment of chronic viral hepatitis. Prog. Liver Dis. 1992; 10: 283-309.
74. Lok AS, Lai CL, Wu PC et al. Alpha-interferon treatment in Chinese patients with chronic hepatitis B. J. Hepatol. 1990; 11: (Suppl. 1): S121-5.
75. de Moura MC, Velosa J, Pinto HC. Is there an alternative to alpha-interferon in chronic hepatitis B? J. Hepatol. 1991; 13 (Suppl. 1): S12-16.
76. Hayashi J, Noguchi A, Nakashima K et al. Human lymphoblastoid and fibroblast interferon in the treatment of chronic hepatitis B. Clin. Ther. 1990; 12: 12-21.
77. Lin SM, Sheen IS, Chien RN, Chu CM, Liaw YF. Long-term beneficial effect of interferon therapy in patients with chronic hepatitis B virus infection. Hepatology 1999; 29: 971-5.
78. Dusheiko GM. Management of chronic hepatitis B and C. S. African Med. J. 1994; 84: 563-70.
79. Liaw YF. Current therapeutic trends in therapy for chronic viral hepatitis. J. Gastroenterol. Hepatol. 1997; 12: S346-53.
80. Zavatglia C, Bottelli R, Bellati G et al. Treatment of chronic hepatitis B (HBeAg-HBV DNA-positive) with lymphoblastoid alpha interferon with or without corti-costeroids: short- and long-term follow-up. Ital. J. Gastroenterol. 1996; 28: 324-31.
81. Lau GK, Carman WF, Locarnini SA et al. Treatment of chronic hepatitis B virus infection: an Asia-Pacific perspective. J. Gastroenter. Hepatol. 1999; 14: 3-12.
82. Management of hepatitis C. NIH consensus statement Mar 24-26 1997; 15: 1-41.
83. Janssen HL, Berk L, Heijtink RA, ten Kate FJ, Schalm SW. Interferon-alpha and zidovudine combination therapy for chronic hepatitis B: results of a randomized, placebo-controlled trial. Hepatology1993; 17: 383-8.
84. Nagai K, Hosaka H, Kubo S, Nakamura N, Shinohara M, Nonaka H. Highly active antiretroviral therapy used to treat concurrent hepatitis B and human immunodeficiency virus infections. J. Gastroenter. 1999; 34: 275-81.
85. Oon CJ, Chen WN, Lim N et al. Hepatitis B virus variants with lamivudine-related mutations in the DNA polymerase and the 'a'epitope of the surface antigen are sensitive to ganciclovir. Antiviral Res. 1999; 41: 113-18.
86. Marques AR, Lau DT, McKenzie R, Straus SE, Hoofnagle JH. Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B. J. Infect. Dis. 1998; 178: 1483-7.
87. Mutimer D, Naoumov N, Honkoop P et al. Combination alpha-interferon and lamivudine therapy or alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J. Hepat. 1998; 28: 923-9.
88. Fontana RJ, Lok AS. Combination therapy for chronic hepatitis B. Hepatology 1997; 26: 234-7.
89. Piqueras B, Salcedo M, Bañares R et al. Famciclovir más interferón en el tratamiento de un paciente con hepatitis crónica por virus B y fallo hepático grave. Revista Espanola De Enfermedades Digestivas 1997; 89: 217-21.
90. Jaeckel E, Manns MP. Experience with lamivudine against hepatitis B virus. Intervirology 1997; 40: 322-36.
91. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J. Hepatol. 1995; 23 (Suppl. 2): 8-12.
92. Davis GL, Esteban-Mur R, Rustgi V et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998; 339: 1493-9.
93. McHutchison JG, Gordon SC, Schiff ER et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N. Engl. J. Med. 1998; 339: 1485-92.
94. Brillanti S, Miglioli M, Barbara L. Combination antiviral therapy with ribavirin and interferon alfa in interferon alfa relapsers and non-responders: Italian experience. J. Hepatol. 1995; (Suppl. 2): 13-15; 15-16.
95. Poynard T, Marcellin P, Lee SS et al. Randomised trial of interferon alpha2b plus placebo for 48 weeks for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet1998; 352: 1426-32.
96. Schvarcz R, Ando Y, Sönnerborg A, Weiland O. Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. J. Hepatol. 1995; 23(Suppl. 2): 17-21.
97. Reichard O, Norkrans G, Frydén A, Braconier JH, Sönnerborg A, Weiland O. Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. Lancet 1998; 351: 83-7.
98. Salmerón J, Ruiz-Extremera A, Torres C et al. Interferon versus ribavirin plus interferon in chronic hepatitis C previously resistant to interferon: a randomized trial. Liver 1999; 19: 275-80.
99. Wright TL. Treatment of hepatitis C: A decision that needs careful consideration. Am. J. Med. 1999; 107: 180-1.
100. Schalm SW, Weiland O, Hansen BE et al. Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis. Gastroenterology 1999; 117: 408-13.
101. Davis GL. Combination therapy with interferon alfa and ribavirin as retreatment of interferon relapse in chronic hepatitis C. Semin. Liver Dis. 1999; 19 (Suppl. 1): 49-55.
102. McHutchison JG, Poynard T. Combination therapy with interferon plus ribavirin for the initial treatment of chronic hepatitis C. Semin. Liver Dis. 1999; 19 (Suppl. 1): 57-65.
103. Gish RG. Standards of treatment in chronic hepatitis C. Semin. Liver Dis. 1999; 19 (Suppl. 1): 35-47.
104. EASL international consensus conference on hepatitis C. J. Hepatol. 1999; 31 (Suppl. 1): 3-8.